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Abstract
Surgical revascularization with coronary artery by-pass grafting is still recommended in vast
majority of patients with unprotected left main disease. The aim of the paper was to analyze
optimal treatment of left main disease in selected groups of patients, on the basis of current
guidelines and information gained from literature data. We focused on data in relation to
treatment of elderly patients, diabetics and those hemodynamically unstable. Additionally we
discussed the issue of anti-platelet therapy and informed consent. As far as efficacy of treatment
is concerned, not only method of revascularization but also general condition of the patient, the
factors influencing peri-operative risk and optimal pharmacotherapy should be taken into
account. Therefore establishment of the heart team is crucial when choosing the most suitable
method of invasive treatment of left main disease. (Cardiol J 2012; 19, 4: 347–354)
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Introduction
Surgical revascularization with vascular grafts is
recommended for vast majority of patients with unpro-
tected significant left main coronary artery stenosis
(ULMS) which is also called unprotected left main di-
sease (ULMD). Then surgery is indicated for the treat-
ment of symptoms and for better prognosis. Technical
progress in interventional cardiology and cardiac sur-
gery, implementation of new generation of anti-proli-
ferative drug eluting stents (DES) and correct monito-
ring of anti-platelet therapy lead to deeper analysis of
the problem. Today, best treatment strategy is chosen
not only on the basis of coronarography result but also
assessment of the overall cardiovascular risk, co-mor-
bid conditions and estimation of long term prognosis.
The aim of this article was to discuss the best
ULMD strategy among particular group of patients,
according to latest recommendations and resear-
ches’ findings.
Methods
This review article was carried out as an
descriptive epidemiological study. Data from
Medline database published till June 2011 were
retrospectively analyzed. Key words used for
searching were as follows: left main, left main
disease, treatment, coronary surgery, percutane-
ous coronary intervention (PCI), and combination
of the aforementioned. English papers were in-
cluded only.
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Coronary artery anatomy
Left main coronary artery (LM, LMCA) aris-
ing from the left sinus of Valsalva is a first branch
of the aorta. Usually its diameter is 3.5–4.5 mm and
length is 10–14 mm, and it braches into left ante-
rior descent artery (LAD) and circumflex artery (Cx)
(Fig. 1). Among 22% of population additional artery
arises at the bifurcation of the LM artery, forming
a trifurcation; third artery is called intermediate ar-
tery (IM) [1]. It is estimated that 0.4% of popula-
tion lacks LM and both arteries arise from separates
origins of the aorta [2]. LM varies in length and
shape. In the Zein’s research based on angio-com-
puted tomography with 3D reconstruction four
types of LM were distinguished: biconcave shape,
tapering morphology, complex morphology and fun-
nel type [3]. Ellipsoid shape in cross section of os-
tial, medial and distal part of LM was found in 94%,
73% and 77% of patients, respectively [3].
Significant left main stenosis
Significant LMCA stenosis (LMS) which is also
called left main disease (LMD) is defined as a re-
duction of at least 50% in the luminal diameter of
the LMCA. LMD is diagnosed in approximately
4–6% of patients undergoing coronarography and
among 1/3 of patients referred to coronary artery
by-pass grafting (CABG). Stenosis is located ostial-
ly, medially or in the bifurcated part in 29%, 19%,
54% of subjects, respectively (Fig. 2). LMD is rarely
presented as an isolated lesion (which concerns
6–8% of coronary patients) but usually (in 70–90%)
coexists with multivessel disease. LMD is more
often related to the proximal than the distal part,
frequently placed in the bifurcation and in more than
50% of cases that are heavily calcified [4]. Among
patients suffering from diffuse atherosclerotic ar-
tery disease LMD is present in 5–9% of the cases.
Isolated LMD is then described in 0.5–1% of those
Figure 1. Morphology of left main; A. Long left main; B. Short left main; C. Trifurcation of left main with intermediate
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subjects [5]. Unprotected LMCA refers to the ves-
sel without any previous intervention, namely with-
out previous by-pass grafting or stenting history.
Current guidelines of left main
disease treatment
According to the European Society of Cardio-
logy (ESC) guidelines from 2006 and American
Heart Association/American College of Cardiology
(AHA/ACC) guidelines from 2009, ULMD was an
absolute indication for surgical revascularization,
regardless of other arteriosclerotic lesions, both to
alleviate the symptoms (I A) and prognosis im-
provement (I A). The guidelines recommended
LMCA angioplasty only in the condition when sur-
gery is not manageable (II b/C), and for the rest of
the cases as alternative revascularization method
with a III B class recommendation [6–8].
This approach was based on randomized trials
results, in which pharmacological vs. invasive treat-
ment (namely balloon angioplasty and bare metal
stent [BMS] implantation techniques) were com-
pared. Based on those data, CABG was superior for
successful treatment for symptoms of angina pecto-
ris. CABG is a well documented and save procedure
with low prevalence of complications and develop-
ment of less invasive techniques helps to reduce time
of hospitalization and costs [9, 10]. Furthermore, it
should be kept in mind that left internal mammary
artery used as an arterial graft is patent in the 90%
of subjects in a 10-year follow-up, along with survi-
val and angina symptoms remission [11].
ESC and AHA/ACC guidelines were rather
skeptic for the use of percutaneous interventions
as methods of treatment of coronary patients. De-
spite attempt to balloon angioplasty followed by
BMS implantation this approach was abandoned
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in ULMD due to unacceptable high risk of re-
stenosis [12].
DES implantation may be risky due to acute
stent thrombosis which can result in sudden cardi-
ac dead in 40% of the patients, if occurred [13–15].
Therefore DES long-term safeness was been re-
cently investigated. It was especially important to
assess the risk of late stent thrombosis, which may
have catastrophic implications in patients treated
for ULMD. According to a multicenter registry of
731 individuals who underwent PCI with DES im-
plantation the risk of thrombosis was 0.95% after
30 months [16]. Similar results were published by
Meliga et al. [17] who described the 3-year risk ra-
tio of 0.6%, 1.1% and 44% for definite, probable and
possible thrombus formation, respectively. Percu-
taneous revascularization is also believed to be su-
perior in patients with high risk of operation (e.g.
porcelain aorta), patients with contradictions to
operation who do not profit from surgery or when
CABG is not available and emergency revascular-
ization is necessary [8].
Despite those above-mentioned concerns,
Food and Drug Administration (FDA) estimate that
60% of DES are used off-label mainly for LMD re-
vascularization which is associated with higher early
and late stent thrombosis (with annual incidence of
1–5%) as well as with higher risk of myocardial in-
farction (MI) and cardiac death [18].
In 2010 ESC Working Group and European
Association for Cardio-thoracic Surgery released
up-to-date guidelines in which recommendations for
treatment of stable coronary disease and acute co-
ronary syndromes (ACS) are presented [19]. In sta-
ble patients LM stenosis (isolated or with bi- or tri-
vessel disease) with low peri-operative risk of death
and patient eligibility for either CABG or PCI,
CABG is strongly indicated (I/A). PCI may be con-
sidered in the case of significant contradictions to
cardiac surgery or patients preferences (IIb/B).
Among patients classified to high risk (SYNTAX
score ≥ 33) with LMD and multivessel disease, PCI
is not recommended (III/B) [19].
It is worth to notice that those recommenda-
tions were modified based on SYNTAX results and
new comparisons between CABG and PCI with anti-
proliferative DES [20–22]. It has been documented
that the risk of death and major adverse cardiac and
cerebro-vascular events (MACCE) is greatest in pa-
tients with the highest SYNTAX score. Moreover,
in patients with the most advanced lesions (third
tertile, i.e. SYNTAX score > 33 points) death and
MACCE occurred significantly more frequently in
PCI than CABG group (for MACCE after 1 year:
23% vs. 10.9%, and after 2 years: 28.2% vs. 15.4%,
after 3 years: 34.1% vs. 19.5% (p < 0.001 for all).
In addition, after 3 years of observation, the differ-
ence in MACCE between PCI and CABG in patients
with a SYNTAX score of 23–32 points (second ter-
tile) was also statistically significant  (27.4% vs.
18.9%, p = 0.02).
Compared to the previous ESC guidelines (say-
ing that ULMD stenting should only be considered
if no other revascularization treatment is possible)
the current recommendations and researches indi-
cate that by favorable anatomical conditions LMCA
stenting procedure can be performed successfully
in patients with stable coronary artery disease
(CAD). Early and late outcomes are not worse,
moreover, in selected groups of patients (SYNTAX
score < 23 points) can be superior to surgical treat-
ment [6, 19, 23].
Also updated ACCF/AHA guidelines suggest
that PCI is only an alternative method of revascu-
larization in carefully selected patients, particular-
ly to improve survival (Ia/C) [24, 25]. Controver-
sies include possibility of treating lesions located
distally in bifurcation or trifurcation which are suit-
able for cardiologist with a grater degree of experi-
ence and expertise [24]. Use of a Heart Team ap-
proach has been recommended in cases in which the
choice of revascularization is not straightforward,
including all ULMD and complex CAD cases [24, 25].
Calculation of the Society of Thoracic Surgeons and
SYNTAX scores which is reasonable in patients with
ULMD and complex CAD, is a class IIa recommen-
dation [25]. In the treatment of patients with STEMI,
when possible, the interventional cardiologist and
cardiac surgeon should decide together on the opti-
mal form of revascularization for these subjects, al-
though it is recognized that these patients are usu-
ally critically ill and therefore not amenable to a pro-
longed deliberation or discussion of treatment
options [24, 25]. Therefore one ought to be cautious
choosing treatment of ULMD with PCI (IIa/C) [25].
Effect of a clinical profile
of patients on prognosis
No useful algorithm which would facilitate the
selection of type of revascularization on the basis
of baseline cardiovascular risk and estimated prog-
nosis has been established yet. Rademacher et al.
[26] analyzed the usefulness of risk stratification
according to EuroSCORE algorithm in patients with
ULMD undergoing PCI. They found that Euro-
SCORE is useless in estimating the risk of 30-day
complications but it can be useful for the evalua-
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tion of a long-term death risk. The risk of death in
a 9-month follow-up was almost 3-fold higher in
patients with EuroSCORE > 5 (28.8%) patients
compared to those with lower EuroSCORE (10.3%).
Studies that assessed treatment with PCI or CABG
revealed that EuroSCORE may be an independent
predictor of MACCE but plays a minor role in de-
termining optimal treatment strategy [26, 27].
White et al. [28] in a cohort of patients undergoing
PCI ULMD or CABG showed that a 30-month sur-
vival without occurrence of an adverse endpoint
(MACCE) was significantly worse in patients with
the highest baseline risk estimated by the Parson-
net scale (i.e. > 15 points), while the overall mor-
tality was significantly higher in patients undergo-
ing PCI with a high risk of Ellis classification (cate-
gory IV).
The Society of Thoracic Surgeons (STS) scale
allows to estimate peri-operative risk of such com-
plications as mortality, stroke, kidney failure, pro-
longed mechanical ventilation or infection accurate-
ly. It was verified only among surgical patients but
could become a useful diagnostic tool to choose the
appropriate method of revascularization, if verified
in PCI LMD group [29].
Left main disease revascularization
in particular groups of patient
On the basis of a 20-year follow-up of patients
with critical LMS undergoing CABG surgery at the
Cleveland Clinic in the years 1971–1998, it has been
proven that the survival was 72% but was signifi-
cantly lower in patients with reduced ejection frac-
tion (< 60%), diabetes, hypertension, peripheral
atherosclerosis, smoking habit, and with elevated le-
vels of triglycerides [30]. Risk for repeated revascu-
larization was 39% and was significantly greater in
younger patients, those with elevated levels of trig-
lycerides and incomplete CABG revascularization.
Diabetics
Diabetes is an equivalent of coronary heart dis-
ease and worsens prognosis in patients with is-
chemic heart disease, regardless of the type of
treatment. Patients with diabetes undergoing
CABG have a greater risk of MACCE (particularly
restenosis) compared with those without diabetes
[31–33]. In addition, those patients have more ad-
vanced changes in coronary vessels (higher SYN-
TAX score) and in case of ULMD they are often
placed in the vessel’s distal segment. Kim et al. [32]
demonstrated that the risk of repeated revasculari-
zation in diabetic patients undergoing PCI is almost
6-folds higher than in the CABG group (respective-
ly: 11.2% and 2%). Also, Hlatky et al. [34] in their
meta-analysis confirmed that for diabetic patients
CABG is superior to PCI in terms of survival and
the incidence of repeated revascularization. The
mortality in a 5-year follow-up was higher in the PCI
group (20%) than in the CABG group (12.3%) with
odds ratio 0.7 (95% CI 0.56–0.87). Additionally, in
a 3-year observation, Meliga et al. [35] showed that
in diabetic patients undergoing PCI of ULMD with
DES MACCE incidence was higher compared to
non-diabetic control group (36.6% vs. 22.4%, re-
spectively). More information are provided by the
results of a 6-year follow-up of the Stent or Surgery
Trial, which documented that the risk of repeated
revascularization is more than 5-folds higher in dia-
betic patients undergoing PCI compared with
CABG (hazard ratio — HR of 5.25) [36]. Similar ef-
fect was observed for mortality rates (HR = 3.11).
In the cited study, however, only 1% of patients had
LMD. Data from the 1-year SYNTAX  follow-up of
diabetic patients with LMD and/or  3-vessel disease
showed higher risk of MACCE among those treat-
ed with PCI compared with CABG (14.2% vs. 26%,
p = 0.003) and significantly higher rate of repeated
revascularization (11.1% vs. 4.1%, p < 0.001) [37].
Mortality among diabetic individuals compared to
those without diabetes was significantly higher,
regardless of the revascularization method: for PCI
they were 8.4% and 3.0%, respectively, and for
CABG: 6.4% vs. 2.6%. Moreover, among  diabetic
LMD patients mortality was higher for those treat-
ed with PCI than CABG (13.5% vs. 4.1%, p = 0.04).
Elderly
In the light of available data it can be assumed
that the use of DES or CABG as a treatment for
ULMD in the elderly is comparable according to
survival. The results of a 2-year follow-up with
a study group of people aged at least 75 years dem-
onstrated similar mortality between CABG and
DES groups (CABG: 17%, DES: 18%), even after
taking into account confounding effect of co-mor-
bidities [38]. In this study, statistically significant
direct predictors of death were: ACS (HR = 2.33),
peripheral vascular disease (HR = 3.05), low ejection
fraction (HR = 0.96) and the risk estimated by Euro-
SCORE algorithm (HR = 1.26 per point increase) or
the Parsonnet’s scale (HR = 1.08 per point increase).
It is worth to notice that the use of DES was asso-
ciated with 8-folds higher risk of repeat revascula-
rization in a DES group (CABG: 3%, DES: 25%).
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Additional results were published by Rhodes-
-Cabaua et al. [39] who observed no difference in
the incidence of cardiac death (CABG: 30.3%, PCI:
34.9%) and the overall MACCE incidence (CABG:
35.2%, PCI: 43.3%) in a 2-year follow-up of 249
patients aged ≥ 80 years with ULMD. In this work,
the only predictor of MACCE was EuroSCORE, re-




Interesting data come from results of a 8-year
observation of patients with ACS and ULMD in the
GRACE study [40]. Both, the 30-day and 6-month
mortality were significantly higher in patients un-
dergoing PCI compared to surgical revasculariza-
tion: for a 30-day follow-up: 11% vs. 5.4% and in
a 6-month observation: 5.4% vs. 1.6%. Also the
6-month incidence of MI was 7-folds higher (4.8%
and 0.7%), and repeated revascularization was
2-folds more frequent (23% and 11.1%) in the
ULMD group after PCI compared to CABG.
In 164 patients with LMD presenting symp-
toms of shock in the course of MI the benefit of
surgical revascularization compared with PCI was
also demonstrated [41]. Despite similar clinical pro-
file (gender, age, co-morbidities, hemodynamic pa-
rameters), a 30-day survival in CABG group was
54%, while in the PCI group it was only 14%. The
benefit was clear despite the significant time discrep-
ancies between onset of MI/cardiogenic shock and
revascularization, which was longer for surgical pa-
tients. Those surgical patients may also benefit from
longer use of intra-aortic balloon counter-pulsation
if only there are no contraindications and risk of com-
plications is low. The authors also conclude that pa-
tients undergoing CABG benefited from full revas-
cularization, which was achieved in 95% of patients.
Moreover, favorable prognosis may come from use
of cardioplegia and cardiac protection during cardio-
pulmonary bypass. That’s why CABG is superior to
PCI in unstable patients with ULMD.
Important results come from Failure in Left
Main Study (FAILS) study that examined the inci-
dence of adverse events among 70 patients under-
going CABG or PCI due to in-stent restenosis in
LMCA [42]. Interestingly, MACCE occurred in
14.3% of CABG patients and in 25.4% of those af-
ter PCI with DES, and in 50% of patients receiving
pharmacotherapy only. Death from any cause oc-
curred in 5.1% patients after PCI, but no death was
noticed after CABG. A new restenosis with the need
of target vessel revascularization occurred in 14.3%
of patients after CABG and 22% of patients after PCI
even if all patients received anti-platelet treatment
after ULMD revascularization.
Appropriate anti-platelet treatment undoubted-
ly has impact on successful PCI treatment of ULMD
[43, 44]. According to current standards, anti-plate-
let therapy in patients undergoing PCI should remain
double with acetylsalicylic acid (ASA) (COX-2 inhi-
bitor) and adenosine receptor antagonist, and its
duration is not clearly specified [44]. After BMS
implantation the treatment should last at least
3 months (in the case of ACS — 12 months) and
after DES implantation a mandatory period of treat-
ment is 12 months. Those patients who underwent
surgical revascularization, even in the case of LMD,
in order to maintain the by-pass patency are only
obliged to receive ASA (150 mg indefinitely). The
additional use of adenosine receptor antagonist is
rather limited and with unproven efficacy. Time
frames presented above, however, are not so obvi-
ous in patients with PCI of ULMD. Lifelong use of
double anti-platelet therapy is postulated due to
high risk of restenosis (especially in BMS) and late
thrombosis (especially in DES).
For those reasons, the use of such a radical
pharmacotherapy is not in doubt. Palmerini et al.
[45] in a cohort of patients after PCI-LMD showed
that most adverse events occurred in patients who
had used dual therapy for less than 6 months and
the risk of death due to acute cardiac events were
more than 4-folds higher during the first 90 days
after discontinuation of clopidogrel, compared with
the later period of discontinuation. But on the oth-
er hand, Chieffo et al. [16] demonstrated that the
use of dual anti-platelet therapy does not necessa-
rily prevent the occurrence of stent thrombosis; at
the time of the incident all subjects received ASA
and clopidogrel, according to the recommendations.
In the study, determinants of thrombosis were as
follows: unstable angina (OR = 3.25), low ejection
fraction (OR = 1.26) and EuroSCORE (OR = 1.18
per point increase). In patients receiving dual anti-
platelet therapy after DES implantation, Park et al.
[46] found no benefit from the treatment lasting
over 12 months. Additionally, it is revealed that
prolonged use of two agents significantly increases
the risk of bleeding, including gastrointestinal he-
morrhage and concomitant use of certain proton pump
inhibitors (especially omeprazole) may alleviate the
desired anti-aggregative effect [47, 48]. Dual ther-
apy may also be a problem for patients with bleed-
ing diathesis. Complex anti-platelet therapy, espe-
cially in a 12-month period (or even longer) also
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generates significant costs (due to limited reim-
bursement of clopidogrel), and at the same time may
impair cooperation between doctor and patient (i.e.
patient compliance and persistence). It is also worth
to mention a study of Migliorini et al. [49] who as-
sessed the impact of high residual platelet activity
(HRPR) on prognosis in patients with ULMD under-
going PCI with a loading dose of 600 mg of clopidogrel.
They found that the presence of high residual activi-
ty after PCI increased risk of death due to infarction
in a 3-year follow-up (HRPR: 28.3% and LRPR: 8%)
and increased risk of stent thrombosis (HRPR: 16%
and LRPR: 4.2%). In the face of the presented data
and due to the absence of clear standards, one logical
option is to optimize therapy by use of regularly re-
peated platelets resistance tests [50].
Informed patient consent
An important point in choosing ULMD treat-
ment strategy is to obtain conscious informed con-
sent of the patient. First of all, one must inform the
patient that the recommended method of revascu-
larization is a surgical technique because we have
strong evidence of its long-term effectiveness and
safety. Undeniably, one need to explain to the pa-
tient the risks of both methods of treatment, includ-
ing trauma of procedures, risk of death and other
cardiac (MI, restenosis, the need of re-intervention)
and non-cardiac (bleeding, renal failure, vascular
problems, stroke) complications. CABG which is
more invasive treatment, should be contrasted with
its documented long-term benefits, what might be
difficult to explain to a patient. Patients should also
realize several facts: the background of the coro-
nary heart disease, the fact that revascularization
with the use of CABG or PCI is only the treatment
of symptoms, he must receive a live-long pharma-
cological treatment (ASA, clopidogrel, statin, beta-
-blocker, ACE inhibitor etc.) and  lifestyle modifica-
tion. It is reasonable to remind the patient the need
of coronary angiography in future (preferably with
intravascular ultrasound), especially after PCI [44].
In light of current data, non-invasive angio-computed
tomography can be performed alternatively [43, 51].
Summary
Coronary artery by-pass surgery remains the
gold standard of treatment of patients with unpro-
tected LMD. PCI may be considered in a vast mi-
nority of individuals. However considering afore-
mentioned data, it should be emphasized that the
long-term effectiveness and safety of the revascu-
larization procedure is determined not only by the
method but also by baseline cardiovascular risk,
general condition of the patient, co-existing mor-
bidity. The latter may increase the risk of compli-
cations even if optimal pharmacotherapy is applied.
Therefore establishment of the heart team is cru-
cial when choosing the most suitable method of in-
vasive treatment of LMD.
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